Established in Barbados in 1997, Lex Caribbean now has offices in the Bahamas, Jamaica, London, and Trinidad and Tobago, and prides itself on being the first pan-Caribbean law firm to provide advice on local law through a variety of jurisdictions. Lex Caribbean's Barbados office specialises in international business, corporate and commercial matters, capital markets, and property development and conveyancing....
[more]
Established in Barbados in 1997, Lex Caribbean now has offices in the Bahamas, Jamaica, London, and Trinidad and Tobago, and prides itself on being the first pan-Caribbean law firm to provide advice on local law through a variety of jurisdictions. Lex Caribbean's Barbados office specialises in international business, corporate and commercial matters, capital markets, and property development and conveyancing.
Over the last 12 months, Lex Caribbean has been involved in several large financings, typically acting for global investment entities. The firm also reports more disposal and acquisition work, much of it generated in the Far East. M&A transactions have focused on the purchase and sale of Barbados entities overseas.
In a deal that closed in December 2010, Lex Caribbean advised the Barbados branch of FirstCaribbean International Bank, as a collateral agent and lender, and Textron Financial Corporation as administrative agent, on the restructuring of a $50 million loan. The loan, to the civic development group Planviron, was completed within an aggressive timeframe. It involved assets located in St Lucia, while the loan agreement was governed by Barbados law. The firm acted under a Chinese wall arrangement, with a separate team acting as Barbados counsel for Textron.
Lex Caribbean also represented Goldman Sachs, Goldman Sachs Lending Partners and Morgan Stanley Senior Funding in Barbados. The firm prepared all the security documents for four Barbados entities - Biovail Holdings International, Biovail Laboratories International, Biovail Laboratories International (Barbados) and Hythe Property - on a credit facility to Valeant Pharmaceuticals International. Under the agreement, the entities acted as guarantors for the obligations of Valeant Pharmaceuticals International. The $2 billion deal closed in September 2010.
[hide]